tRNA-derived fragment tRF-17-8SPOL52 induces resistance to bortezomib in multiple myeloma via autophagy activation.

Fu Y, Qiao Z, Xiao Y, Liang T, Xu C · 2026 · Biochimica et biophysica acta. Molecular basis of disease · Atlas ID FU2026

What this study shows

tRF-17-8SPOL52 tsRNA is upregulated in relapsed/refractory myeloma and drives bortezomib resistance by suppressing RUBCN (a negative autophagy regulator), thereby activating autophagy flux.

Abstract

ShowHide

Drug resistance limits the long-term survival of patients with multiple myeloma. The role of tRNA-derived fragments (tsRNAs) in bortezomib resistance in myeloma remains unknown. tRF-17-8SPOL52 was identified as the most highly expressed tsRNA in relapsed/refractory myeloma. tRF-17-8SPOL52 promoted bortezomib resistance in vitro and in vivo. Ago-RIP-sequencing and dual-luciferase reporter assay showed that tRF-17-8SPOL52 negatively regulated RUBCN. The regulation of RUBCN by tRF-17-8SPOL52 was Ago-dependent.

Read the full abstract on PubMed →

At a glance

Evidence type	M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: Human (myeloma cell lines + patient samples)) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is.
Study type	5 - Mechanistic / In Vitro
Model system	Human (myeloma cell lines + patient samples)
Journal	Biochimica et biophysica acta. Molecular basis of disease
Year	2026
Peer reviewed	Yes
Record last updated	2026-10-01
Source	DOI 10.1016/j.bbadis.2026.168396 · PMID 42551544

Extracted findings

These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.

Intervention	tRF-17-8SPOL52 (tsRNA)
Target	RUBCN / autophagy
Model	Human (myeloma)
Effect	Activates autophagy via RUBCN suppression, inducing bortezomib resistance

In the Atlas

Cite this paper

ShowHide

Fu, Y., Qiao, Z., Xiao, Y., Liang, T., & Xu, C. (2026). tRNA-derived fragment tRF-17-8SPOL52 induces resistance to bortezomib in multiple myeloma via autophagy activation. Biochimica et biophysica acta. Molecular basis of disease. https://doi.org/10.1016/j.bbadis.2026.168396

@article{FU2026,
  author       = {Fu, Y. and Qiao, Z. and Xiao, Y. and Liang, T. and Xu, C.},
  title        = {{tRNA-derived fragment tRF-17-8SPOL52 induces resistance to bortezomib in multiple myeloma via autophagy activation}},
  journal      = {Biochimica et biophysica acta. Molecular basis of disease},
  year         = {2026},
  doi          = {10.1016/j.bbadis.2026.168396},
  note         = {PMID: 42551544},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record FU2026) [Data set]. https://mtor-atlas.org/study/FU2026/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_FU2026,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record FU2026},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/FU2026/},
  doi          = {10.5281/zenodo.22059963}
}

Was this page useful?